BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30638912)

  • 1. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
    King MT; Yang DD; Muralidhar V; Mahal B; Butler S; Devlin PM; Lee LJ; Mouw KW; Martin NM; D'Amico AV; Nguyen PL; Orio PF
    Brachytherapy; 2019; 18(2):186-191. PubMed ID: 30638912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?
    Morton GC; Hoskin PJ
    Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):474-82. PubMed ID: 23727431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
    Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
    Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.
    Khor R; Duchesne G; Tai KH; Foroudi F; Chander S; Van Dyk S; Garth M; Williams S
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):679-85. PubMed ID: 22954770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.
    Petereit DG; Sarkaria JN; Potter DM; Schink JC
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1267-74. PubMed ID: 10613322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients.
    Marina O; Gustafson GS; Kestin LL; Brabbins DS; Chen PY; Ye H; Martinez AA; Ghilezan MI; Wallace M; Krauss DJ
    Brachytherapy; 2014; 13(1):59-67. PubMed ID: 23871661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose rate brachytherapy boost for prostate cancer: a systematic review.
    Zaorsky NG; Doyle LA; Yamoah K; Andrel JA; Trabulsi EJ; Hurwitz MD; Dicker AP; Den RB
    Cancer Treat Rev; 2014 Apr; 40(3):414-25. PubMed ID: 24231548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer.
    Kestin LL; Martinez AA; Stromberg JS; Edmundson GK; Gustafson GS; Brabbins DS; Chen PY; Vicini FA
    J Clin Oncol; 2000 Aug; 18(15):2869-80. PubMed ID: 10920135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
    Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
    Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
    King CR
    Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
    Morton G; Loblaw A; Cheung P; Szumacher E; Chahal M; Danjoux C; Chung HT; Deabreu A; Mamedov A; Zhang L; Sankreacha R; Vigneault E; Springer C
    Radiother Oncol; 2011 Sep; 100(3):463-7. PubMed ID: 21924511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.
    Martinez AA; Gustafson G; Gonzalez J; Armour E; Mitchell C; Edmundson G; Spencer W; Stromberg J; Huang R; Vicini F
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):316-27. PubMed ID: 12023135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.
    Zaorsky NG; Den RB; Doyle LA; Dicker AP; Hurwitz MD
    Expert Rev Med Devices; 2013 Nov; 10(6):751-63. PubMed ID: 24195459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.
    Wang X; Liu R; Ma B; Yang K; Tian J; Jiang L; Bai ZG; Hao XY; Wang J; Li J; Sun SL; Yin H
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007563. PubMed ID: 20614461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.